Johnson & Johnson

Yahoo Finance • 1 hour ago

Wall Street’s push to bring private assets to 401(k)s faces investor apathy: WSJ

[Person holding tablet, business concept] ra2studio/iStock via Getty Images Major asset managers are eager to open the door for ordinary Americans to invest in private-market assets such as private equity and private credit, investments h... Full story

Yahoo Finance • 2 hours ago

Earnings week ahead: JPM, C, WFC, GS, MS, WFC, TSM, JNJ, SLB, and more

[Young blond female manager explaining quarterly results on large led screen] NicolasMcComber Earnings season heats up in mid-October, featuring results from a stellar lineup of companies across various sectors. This week's highlights inc... Full story

Yahoo Finance • 2 hours ago

Stocks dip as government shutdown continues, rare earths rally: What to watch this week

The stock market will enter the second full week of the government shutdown following a tariff-driven selloff Friday. At the closing bell, the S&P 500 (^GSPC), tech-heavy Nasdaq Composite (^IXIC), and small cap-focused Russell 2000 (^RUT)... Full story

Yahoo Finance • 16 hours ago

Notable healthcare headlines for the week: Novo Nordisk, Bristol Myers Squibb and J&J in focus

Tom Werner Wall Street's major averages plummeted on Friday after U.S. President Donald Trump threatened higher tariffs to China, saying it had "become very hostile" sending letters to other countries wanting to "impose export controls."... Full story

Yahoo Finance • 19 hours ago

Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more

Here's a list of key deals reported across sectors this week: * Protagonist Therapeutics (NASDAQ:PTGX [https://seekingalpha.com/symbol/PTGX]), a biotech focused on peptide-based therapeutics, traded ~30% higher on Friday after The Wall... Full story

Yahoo Finance • 2 days ago

Johnson & Johnson recommends shareholders reject "mini-tender" offer by Tutanota

NEW BRUNSWICK, N.J., October 10, 2025--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC, a limited liability company established pursuant to the... Full story

Yahoo Finance • 2 days ago

Protagonist Stock Surges on Johnson & Johnson Report

Protagonist Therapeutics shares soared more than 30% Friday after The Wall Street Journal reported that the biopharma company was in talks with Johnson & Johnson about a possible acquistion. See more ... Continue Reading Visualizza comme... Full story

Yahoo Finance • 2 days ago

Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index down 1.4% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 days ago

See Which Of The Latest 13F Filers Holds JNJ

At Holdings Channel, we have reviewed the latest batch of the 20 most recent 13F filings for the 03/31/2025 reporting period, and noticed that Johnson & Johnson (Symbol: JNJ) was held by 13 of these funds. When hedge fund managers appear... Full story

Yahoo Finance • 2 days ago

Trump's China tariff threat sinks stocks, Applied Digital surges

Yahoo Finance Anchor Josh Lipton reports on three stories Wall Street is watching in the latest Market Minute: US stocks tumble as US-China trade tensions intensify, Protagonist Therapeutic (PTGX) shares surge on WSJ reports of acquisition... Full story

Yahoo Finance • 2 days ago

Sector Update: Health Care Stocks Decline Friday Afternoon

Health care stocks were lower Friday afternoon, with the NYSE Health Care Index and the Health Care PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 2 days ago

Top Midday Gainers

Quoin Pharmaceuticals (QNRX) shares soared 126% amid heavy trading intraday after the company said F PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 days ago

Top Midday Stories: Trump Threatens 'Massive' Tariff Raise on China; Nvidia Chips Face Higher Scrutiny at China Customs

All three major US stock indexes were in the red around midday trading Friday, with the Nasdaq Compo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 days ago

Protagonist Therapeutics stock surges after J&J acquisition talks report

Investing.com -- Protagonist Therapeutics (NASDAQ:PTGX) stock spiked 10% before being halted for volatility after The Wall Street Journal reported that Johnson & Johnson (NYSE:JNJ) is in talks to acquire the biotech company. The potential... Full story

Yahoo Finance • 2 days ago

Stocks to watch next week: JPMorgan, TSMC, Infosys, ASML and Bellway

A packed week of earnings is set to provide investors with fresh insights into the state of the global economy, as major companies across various sectors and geographies prepare to report. In the US, JPMorgan Chase (JPM), the country’s la... Full story

Yahoo Finance • 2 days ago

J&J reportedly in talks to buy Protagonist

Protagonist Therapeutics (NASDAQ:PTGX [https://seekingalpha.com/symbol/PTGX]), a biotech focused on peptide-based therapeutics, traded ~30% higher on Friday after The Wall Street Journal reported that Johnson & Johnson (NYSE:JNJ [https://s... Full story

Yahoo Finance • 2 days ago

Validea Detailed Fundamental Analysis - JNJ

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks... Full story

Yahoo Finance • 2 days ago

Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress

17 abstracts from across the Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression New post-hoc analysis of CAPLYTA® (lumateperone) Phase 3 data evaluat... Full story

Yahoo Finance • 3 days ago

New AI solution offers real-time peek into the mind of clinical trial participants

Cognivia Signal expected to reduce trial dropout risk and placebo impact for pharma and biotech trial sponsors. MONT-SAINT-GUIBERT, Belgium, Oct. 9, 2025 /PRNewswire/ -- Cognivia, an innovative AI company dedicated to helping clinical tri... Full story

Yahoo Finance • 3 days ago

Guru Fundamental Report for JNJ

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. This strategy looks fo... Full story